Post‐hoc analysis of the tofogliflozin post‐marketing surveillance study (J‐STEP/LT): Tofogliflozin improves liver function in type 2 diabetes patients regardless of BMI

Post‐hoc analysis of the tofogliflozin post‐marketing surveillance study (J‐STEP/LT): Tofogliflozin improves liver function in type 2 diabetes patients regardless of BMI

ABSTRACT Aims/Introduction Patients with type 2 diabetes are at high risk of developing steatotic liver disease (SLD). Weight loss has proven effective in treating metabolic dysfunction‐associated steatotic liver disease (MASLD) in obese patients with type 2 diabetes, with sodium‐glucose cotransport...

Full description

Saved in:
Bibliographic Details
Main Authors: Hiroyuki Uchinuma, Mitsunori Matsushita, Masaya Tanahashi, Hideki Suganami, Kazunori Utsunomiya, Kohei Kaku, Kyoichiro Tsuchiya
Format: Article
Language:English
Published: Wiley 2025-04-01
Series:Journal of Diabetes Investigation
Subjects:
BMI
MASLD
SGLT2 inhibitors
Online Access:https://doi.org/10.1111/jdi.14402
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1111/jdi.14402

Similar Items